INT106382

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 2002
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 13
Total Number 15
Disease Relevance 5.18
Pain Relevance 0.56

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (NME1) cytosol (NME1) mitochondrion (NME1)
small molecule metabolic process (NME1) nucleus (NME1) kinase activity (NME1)
Anatomy Link Frequency
EM-2 2
SW480 1
colon 1
NME1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 2 94.00 High High
opioid receptor 2 88.00 High High
imagery 9 82.96 Quite High
Perioperative pain 6 75.12 Quite High
cINOD 7 72.16 Quite High
Analgesic 4 68.16 Quite High
aspirin 15 50.00 Quite Low
Potency 2 36.56 Quite Low
Pain 6 28.24 Quite Low
COX2 3 10.00 Low Low
Disease Link Frequency Relevance Heat
Nasopharynx Cancer 290 99.20 Very High Very High Very High
Breast Cancer 18 98.76 Very High Very High Very High
Stomach Cancer 6 96.48 Very High Very High Very High
Papillomavirus Infection 1 95.48 Very High Very High Very High
Cervical Cancer 2 94.76 High High
Fibromyalgia 2 91.60 High High
Cancer 125 88.80 High High
Epstein-barr Virus 88 87.16 High High
Colon Cancer 10 81.28 Quite High
Apoptosis 25 78.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
After treatment with ASA, down-regulation of Bcl2 and CD44v6 expression and up-regulation of nm23 expression were observed in SW480 cells.
Gene_expression (expression) of nm23 in SW480
1) Confidence 0.66 Published 2002 Journal Eur. J. Clin. Invest. Section Body Doc Link 12423325 Disease Relevance 0.13 Pain Relevance 0
Decreased CEA content and CD44v6 expression and elevated nm23 expression may contribute to the effect of ASA on invasive potential of SW480 colon cancer cells.


Gene_expression (expression) of nm23 in colon
2) Confidence 0.66 Published 2002 Journal Eur. J. Clin. Invest. Section Body Doc Link 12423325 Disease Relevance 0 Pain Relevance 0
Expression of Bcl2, Bax, CD44v6, and nm23 were evaluated by immunocytochemistry.
Gene_expression (Expression) of nm23
3) Confidence 0.66 Published 2002 Journal Eur. J. Clin. Invest. Section Body Doc Link 12423325 Disease Relevance 0.16 Pain Relevance 0
Additionally of note is up-regulation of the antimetastatic gene product NM23, which is frequently methylated and silenced in patients with breast cancer [66].
Gene_expression (methylated) of NM23 associated with breast cancer
4) Confidence 0.65 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762324 Disease Relevance 1.02 Pain Relevance 0
In addition, the expression pattern of Id-1 was inversely related to that of nm23.
Gene_expression (expression) of nm23
5) Confidence 0.54 Published 2006 Journal Int. J. Cancer Section Abstract Doc Link 16184548 Disease Relevance 0.68 Pain Relevance 0.07
Product and process innovation appears in small, incremental steps" [2].
Gene_expression (Product) of process innovation
6) Confidence 0.14 Published 2007 Journal J Cardiothorac Surg Section Body Doc Link PMC2048505 Disease Relevance 0.07 Pain Relevance 0
Their model describes three phases of product and process innovation that form a general pattern.
Gene_expression (product) of process innovation
7) Confidence 0.14 Published 2007 Journal J Cardiothorac Surg Section Body Doc Link PMC2048505 Disease Relevance 0 Pain Relevance 0
The expressions of nm23-H1 and VEGF protein were examined by immunohistochemistry S-P staining in NPC tissues.
Spec (examined) Gene_expression (expressions) of nm23-H1 associated with nasopharynx cancer
8) Confidence 0.09 Published 2007 Journal Mol Cancer Section Body Doc Link PMC1774581 Disease Relevance 1.53 Pain Relevance 0
The low level expression of nm23-H1 protein and the high level expression of VEGF protein might be associated with the development and poor prognosis of NPC [55].
Gene_expression (expression) of nm23-H1 associated with nasopharynx cancer
9) Confidence 0.09 Published 2007 Journal Mol Cancer Section Body Doc Link PMC1774581 Disease Relevance 1.51 Pain Relevance 0
Thus, eIND differs from conventional IND in the sense that the NME are introduced firstly in humans in non-pharmacologic doses (phase 0) instead of conventional phase I studies, where NME is given in therapeutic doses.
Gene_expression (introduced) of NME
10) Confidence 0.07 Published 2010 Journal Journal of Pharmacy and Bioallied Sciences Section Body Doc Link PMC2996064 Disease Relevance 0 Pain Relevance 0.04
Less than 10% of applications for INDs for NME progress beyond the investigational stage to submission of NDA.[25]
Gene_expression (progress) of NME
11) Confidence 0.07 Published 2010 Journal Journal of Pharmacy and Bioallied Sciences Section Body Doc Link PMC2996064 Disease Relevance 0 Pain Relevance 0.03
Vd(ss) was 2.0+/-4.93, 1.7+/-2.5, 7.0+/-5.2 and 6.7+/-2.2 l/kg in NB, IF1, IF2 and YC respectively.
Gene_expression (respectively) of NB
12) Confidence 0.04 Published 2006 Journal Eur. J. Pediatr. Section Abstract Doc Link 16496200 Disease Relevance 0.08 Pain Relevance 0.14
Cl(t) was 15.9+/-16.7, 46.6+/-76.9, 235.5+/-454.1 and 338+/-168.1 ml/min in NB, IF1, IF2 and YC respectively.
Gene_expression (respectively) of NB
13) Confidence 0.04 Published 2006 Journal Eur. J. Pediatr. Section Abstract Doc Link 16496200 Disease Relevance 0 Pain Relevance 0
A series of endomorphin-1 (EM-1) and endomorphin-2 (EM-2) analogues, containing non-cyclic amino acids (Ala, D-Ala, beta-Ala, NMeAla, D-NMeAla or Sar) instead of Pro in position 2 was synthesized, where NMeAla = N-methylalanine and Sar = N-methylglycine, sarcosine.
Gene_expression (synthesized) of NMeAla in EM-2
14) Confidence 0.00 Published 2010 Journal Basic Clin. Pharmacol. Toxicol. Section Abstract Doc Link 19874287 Disease Relevance 0 Pain Relevance 0.14
A series of endomorphin-1 (EM-1) and endomorphin-2 (EM-2) analogues, containing non-cyclic amino acids (Ala, D-Ala, beta-Ala, NMeAla, D-NMeAla or Sar) instead of Pro in position 2 was synthesized, where NMeAla = N-methylalanine and Sar = N-methylglycine, sarcosine.
Gene_expression (synthesized) of NMeAla in EM-2
15) Confidence 0.00 Published 2010 Journal Basic Clin. Pharmacol. Toxicol. Section Abstract Doc Link 19874287 Disease Relevance 0 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox